Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

t sectors potentially served by AHRO-001 include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's pipeline, milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano ... the latest genomics research centers to purchase an ... Institute, the National Cancer Institute (NCI), NIH Intramural ... Center). Before Irys, obtaining a comprehensive view of ... generation sequencing (NGS) does not deliver the scalability ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... Vantage Health (OTC BB: VNTH), ("Vantage"), ("company") announced today ... officials from the Ministry of Health and Social Welfare, ... all representing the United Republic of Tanzania ("URT") which ... formal Public Private Partnership ("PPP") Agreement between Vantage, its ...
... 2011 AAPC Physician Services ( www.aapcps.com ) recently ... to help busy medical practices simplify adherence to ... physician practice setting we are bombarded with compliance issues ... Schwebach, VP of AAPC Physician Services. "This compliance toolkit ...
Cached Medicine Technology:Tanzania Minister of Health, on Behalf of the Government, Promises Full Support to Vantage Health in the United Republic of Tanzania 2Tanzania Minister of Health, on Behalf of the Government, Promises Full Support to Vantage Health in the United Republic of Tanzania 3Tanzania Minister of Health, on Behalf of the Government, Promises Full Support to Vantage Health in the United Republic of Tanzania 4
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... Morphotek(R), Inc., a subsidiary of Eisai ... Food and Drug Administration (FDA) has agreed to and ... clinical trial evaluating farletuzumab (also known as MORAb-003) in ... agreement was made under the Special Protocol Assessment (SPA) ...
... WebMD Health Corp. (Nasdaq: WBMD ), the ... States, today announced a long-term strategic relationship with Boots ... in the United Kingdom, to jointly develop a consumer ... new joint offering will leverage WebMD,s online consumer health ...
... Issues Alert maintaining recommendation in support of LCA,s current ... LCA-Vision Inc. (Nasdaq: LCAV ) announces that ... affirming its recommendation that LCA-Vision stockholders vote ... reject all proposals, including the removal of the current ...
... March 23 Medical images are increasingly ... digitised medical images poses an immense challenge ... It is essential that image archive storage ... (PACS) vendors and image modality manufacturers become ...
... news is the best news that we have been waiting ... of the medication through Sinus Dynamics.WESTLAKE VILLAGE, Calif., March 23 ... have always asked if it would be better to have ... and penetrated into the sinuses. Now this fantastic news and ...
... States is in dire need of more physicians. But ... problem, the report points out that the issue cannot ... or expanding existing schools. For more than 30 ... qualified students, who show the commitment and determination to ...
Cached Medicine News:Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 2Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 3Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 4Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 2Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 4Health News:New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:Ross University School of Medicine Succeeds Where Others Fall Short, According to Standards Established in New Report 2Health News:Ross University School of Medicine Succeeds Where Others Fall Short, According to Standards Established in New Report 3
... The S7 with Discrete Technology Coronary ... unmatched scaffolding. Proprietary Secure Technology stent ... pillows that partially encapsulate the stent ... Technology is designed to minimize balloon ...
Unique Radial Tandem Architecture Stent Design for enhanced flexibility and force characteristics....
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
Medicine Products: